semaglutide 2.4 mg weekly Efficacy and safety of once-weekly 2·4 versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial Efficacy and safety of once-weekly

In a population pharmacokinetic analysis of plasma dofetilide concentrations, the mean dofetilide clearance of dofetilide was 16% lower in patients on thiazide diuretics

Our Team Meet Your Care Team Tamer Yacoub, MD,FACE Provider Jennifer Gillis, MSN, ANP-c Provider Victoria Almeida, FNP Provider Tiara Rozario, MA Clinical Staff Glenda Arruda Office Staff Questions

In 2017, Lars Fruergaard Jrgensen became Novo Nordisk's new chief executive, only the fourth person to hold the role as CEO since the merger in 1989

Arundati from Hyderabad experienced significant weight loss after struggling with intermittent fasting

June 17, 2024: Wegovy Lawsuit Progresses with First Status Conference Under New Judge Karen Marston On June 10, 2024, the new judge, Karen Marston, held the first status conference in the Wegovy lawsuit since Judge Pratters passing

Inclusion Criteria Age 16 or older Has completed at least 6 months of structured lifestyle therapy (nutrition, activity, or behavioral support) without achieving desired results Family and teen are willing to commit to a structured program including injections, monitoring, and follow-up care BMI at or above the 95th percentile for age and gender, or above the 85th percentile with health-related conditions such as insulin resistance or high cholesterol